Minimizing Risk & Accelerating Timelines in Oncology Trials
Cancer has an etiology that involves a wide range of genetic interactions and dysfunction across multiple systems. These characteristics make [...]
Free Medical Science Liaison (MSL) and MSL Manager Mentor Program
The MSL Mentor Program is a unique program, provided free of charge, that exemplifies The Medical Science Liaison Society's mission [...]
[Webinar] Conducting Qualification and Validation in the Era of Covid-19
In a process known as qualification and validation, regulatory agencies such as FDA, EMA and WHO, require that the pharmaceutical, [...]
[Whitepaper] How Can Real-World Evidence Support Adoption of New Technology?
The application of real-world evidence (RWE) as a healthcare decision-making tool has the potential to significantly improve patient outcomes, patient [...]
Bayesian Methods for Multiple Cohort Expansion (MuCE) designs
Cohort expansion trials where multiple dose(s) and multiple indication(s) need to be tested in parallel can present complex problems for [...]
Fabio Pammolli Summarizes Research on Pharma R&D
According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, [...]
EVERSANA Implements Holistic Commercialization Strategies
EVERSANA, the leading provider of global services to the life sciences industry, is developing an integrated and independent commercial services [...]
ICER Finds That Supervised Injection Facilities Save Lives and Money
ICER has concluded that there is sufficient evidence demonstrating that supervised injection facilities (SIFs) prevent overdose deaths and reduce overall [...]
The Emergence of ICER in American Pharma
Joe Biden recently suggested that Medicare drug-price negotiations should follow the German model where negotiations between government and drugmakers are informed [...]
Michael L. Ryan of Bristol Myers Squibb Elected Board Chair of National Pharmaceutical Council
Today the National Pharmaceutical Council (NPC) announced that Michael L. Ryan, PharmD, Senior Vice President, Worldwide Value, Access, Pricing and [...]
Advanced Design Framework with Yannis Jemiai
The clinical trial design process has been irrevocably altered by cloud-based computing. Until recently, it would take a statistician a [...]
[Webinar] How Health Care Innovation Affects Life Expectancy and Patient Well-Being
The American Journal of Managed Care® recently hosted a webinar entitled "Bang for the Buck: How Health Care Innovation Affects [...]
ICER Releases Draft Evidence Report on Treatments for High Cholesterol
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report evaluating the comparative clinical effectiveness and [...]
[Podcast] How To Best Launch a Therapy For an Ultra-rare Disease?
In a special episode of Beyond the Molecule, Fishawack Health explores the rare disease space to reveal the perspectives of two [...]
How to Develop the Right Drugs and How to Pay for Them
Tune in to this health care podcast with drug affordability expert Dr. Bruce Rector as he discusses how to leverage [...]
COVID-19: Second Assessment Update
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
Huntsworth Acquires Nucleus Global
Huntsworth, an international healthcare and communications group, has announced an agreement to acquire Nucleus Global, one of the largest medical [...]
Value Assessment in the Context of COVID-19
Efforts to rapidly respond to the coronavirus pandemic have highlighted the need for credible, relevant, and timely information on the [...]
[Podcast] Is Fee-For-Service the Smoking Gun for U.S. Health Care Spending?
It is no secret that fee-for-service models incentivize physicians and health systems to perform more tasks than may be needed. [...]
What to know as ACA heads to the Supreme Court
On Tuesday, oral arguments began in the Supreme Court and the stakes could not be higher: the very fate of [...]
ICER Releases Statement on Racism in America
The Institute for Clinical and Economic Review (ICER) has pledged to do its part to combat institutionalized and systemic racism. [...]
Indication-Based Pricing Gaining Support in UK
A cross-sector expert panel to improve patient access to innovative cancer medicines in the UK recommended that drug prices should [...]
ICER Provides Second Update to Pricing Models for Remdesivir
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
[ICON White Paper] ICER’s Impact on Payer Decision-making
The Institute for Clinical and Economic Review (ICER) fills a gaping void for Health Technology Assessment in the United States. [...]
The Patient Not in the Room
Since 2009, the amount that workers pay for health insurance has increased 71% while wages have increased 26%--yet another demonstration [...]